Praxis Precision Medicines to Present at J.P. Morgan Healthcare Conference
Praxis Precision Medicines (NASDAQ: PRAX) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference. The company, which focuses on developing therapies for central nervous system (CNS) disorders, will present a corporate overview at the conference on January 15, 2025, at 2:15pm PST at the Westin St. Francis Hotel in San Francisco.
The presentation will be accessible through a live webcast, and a replay will remain available for 30 days through the company's website at www.praxismedicines.com in the Investors + Media section under 'Upcoming & Recent Events'.
Praxis Precision Medicines (NASDAQ: PRAX) ha annunciato la sua partecipazione alla 43ª Conferenza Sanitaria Annuale J.P. Morgan. L'azienda, che si concentra sullo sviluppo di terapie per i disturbi del sistema nervoso centrale (SNC), presenterà una panoramica aziendale durante la conferenza il 15 gennaio 2025, alle 14:15 PST presso il Westin St. Francis Hotel a San Francisco.
La presentazione sarà disponibile tramite un webcast dal vivo, e una registrazione sarà accessibile per 30 giorni attraverso il sito web dell'azienda all'indirizzo www.praxismedicines.com nella sezione Investitori + Media sotto 'Eventi Futura & Recenti'.
Praxis Precision Medicines (NASDAQ: PRAX) ha anunciado su participación en la 43ª Conferencia Anual de Atención Médica J.P. Morgan. La compañía, que se centra en desarrollar terapias para trastornos del sistema nervioso central (SNC), presentará una visión general de la empresa en la conferencia el 15 de enero de 2025, a las 14:15 PST en el Hotel Westin St. Francis en San Francisco.
La presentación será accesible a través de una transmisión en vivo, y se mantendrá disponible para su reproducción durante 30 días en el sitio web de la empresa en www.praxismedicines.com en la sección Inversores + Medios bajo 'Próximos y Eventos Recientes'.
프랙시스 프리시전 의약품 (NASDAQ: PRAX)은 제43회 JP모건 헬스케어 콘퍼런스에 참여할 것이라고 발표했습니다. 중추신경계(CNS) 질환에 대한 치료제 개발에 집중하는 이 회사는 2025년 1월 15일 오후 2시 15분 PST에 샌프란시스코의 웨스틴 세인트프랜시스 호텔에서 콘퍼런스에서 기업 개요를 발표할 예정입니다.
발표는 실시간 웹캐스트를 통해 접근할 수 있으며, 회사 웹사이트 www.praxismedicines.com의 투자자 + 미디어 섹션의 '다가오는 및 최근 이벤트'에서 30일 동안 다시 시청할 수 있습니다.
Praxis Precision Medicines (NASDAQ: PRAX) a annoncé sa participation à la 43ème Conférence Annuelle J.P. Morgan sur la Santé. L'entreprise, qui se concentre sur le développement de thérapies pour les troubles du système nerveux central (SNC), présentera un aperçu de l'entreprise lors de la conférence le 15 janvier 2025 à 14h15 PST à l'hôtel Westin St. Francis à San Francisco.
La présentation sera accessible via un webcast en direct, et un replay sera disponible pendant 30 jours sur le site web de l'entreprise à www.praxismedicines.com dans la section Investisseurs + Médias sous 'Événements à Venir & Récents'.
Praxis Precision Medicines (NASDAQ: PRAX) hat seine Teilnahme an der 43. J.P. Morgan Healthcare Conference angekündigt. Das Unternehmen, das sich auf die Entwicklung von Therapien für Störungen des zentralen Nervensystems (ZNS) konzentriert, wird am 15. Januar 2025 um 14:15 Uhr PST im Westin St. Francis Hotel in San Francisco einen Unternehmensüberblick präsentieren.
Die Präsentation wird über ein Live-Webcast zugänglich sein, und eine Wiederholung wird für 30 Tage über die Unternehmenswebsite unter www.praxismedicines.com im Bereich Investoren + Medien unter 'Zukünftige & Aktuelle Veranstaltungen' verfügbar sein.
- None.
- None.
BOSTON, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced that it will be presenting a corporate overview at the 43rd Annual J.P. Morgan Healthcare Conference taking place in San Francisco, CA at the Westin St. Francis Hotel on Wednesday, January 15, 2025 at 2:15pm PST.
A live webcast of the event will be available through this link. A replay of the event will also be available through the “Upcoming & Recent Events” page of the Investors + Media section of the company’s website at www.praxismedicines.com, for 30 days.
About Praxis
Praxis Precision Medicines is a clinical-stage biopharmaceutical company translating insights from genetic epilepsies into the development of therapies for CNS disorders characterized by neuronal excitation-inhibition imbalance. Praxis is applying genetic insights to the discovery and development of therapies for rare and more prevalent neurological disorders through our proprietary small molecule platform, Cerebrum™, and antisense oligonucleotide (ASO) platform, Solidus™, using our understanding of shared biological targets and circuits in the brain. Praxis has established a diversified, multimodal CNS portfolio including multiple programs across movement disorders and epilepsy, with four clinical-stage product candidates. For more information, please visit www.praxismedicines.com and follow us on Facebook, LinkedIn and Twitter/X.
FAQ
When and where will Praxis Precision Medicines (PRAX) present at the J.P. Morgan Healthcare Conference?
How can investors access Praxis Precision Medicines' (PRAX) J.P. Morgan Healthcare Conference presentation?
What is the focus area of Praxis Precision Medicines' (PRAX) drug development?
How long will the replay of PRAX's J.P. Morgan Healthcare Conference presentation be available?
